RATIONALE: The objective of this study was to assess the impact of a multi-disciplinary school-based health care delivery model on outcomes in elementary school subjects with asthma. METHODS: Subjects with physician diagnosed asthma were recruited from two local school districts. In-school visits occurred at baseline and at 2, 4, 8 and 12 weeks. At each visit, the allergy/asthma specialist conducted a medical assessment and adjusted drug therapy according to NHLBI-EP3 and the study pharmacist provided disease and medication specific education. Asthma severity/control, knowledge and compliance were assessed at each visit. RESULTS: Fifty subjects enrolled (mean age 8.961.7 years, 52% male, 62% minority) and 23 had persistent asthma. 92.0% of subjects were complaint with > _80% of visits (P50.011). In those with persistent asthma, use of controller therapy increased from 21.4% to 78.5% before and after baseline, respectively (P<0.01). 6.1% and 60.0% of subjects had complete knowledge at baseline and final visits, respectively (P<0.001). 37.8% and 65.7% of caregivers had complete knowledge at baseline and final visits, respectively (P50.01). Asthma control test scores improved from 20.063.6 to 22.963.4 before and after baseline, respectively (P<0.001). CONCLUSIONS: In summary, compliance with school-based visits was very high and asthma knowledge and disease control improved significantly. Future studies need to examine the impact of this specific multidisciplinary school based intervention on morbidity outcomes such as disease exacerbations, acute visits and hospitalizations.
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Lower socioeconomic status predicts lower pneumococcal antibody titers among young adults with asthma Dept of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN. RATIONALE: Despite the significantly increased risk of invasive pneumococcal disease among patients with asthma, the association of socio-economic status (SES) with antibody titers is not known. We conducted a prospective study to assess the association of pneumococcal titers and immune response to PPSV23 to SES. METHODS: We prospectively enrolled 50 asthmatics between 19-21 years old that did not have a history of PPSV23 from Mayo Clinic primary care practice. One person in 50 had PCV-7 while none had PCV-13 immunization in childhood. Pneumococcal titers for 23 serotypes were measured at baseline and 6 weeks post vaccination. SES was measured by HOUSES, a validated individual-level housing-based SES index (the higher HOUSES, the greater SES). The study approval and oversight was by the Mayo Clinic IRB. RESULTS: Asthma control test (ACT) scores at baseline did not differ by SES measured by HOUSES among subjects. A majority of baseline titers of PPSV23 showed positive association with HOUSES (P<0.05 for 7 titers: 1, 10A, 12F, 15B, 18C, 19F, 22F, 5, 7F, 8 and p: 0.05-0.1 for 4 titers: 23F, 3, 9N and 9V). Fold change of 20 out of 23 titers showed no association with HOUSES. CONCLUSIONS: Lower SES is associated with lower baseline PPSV23 titers and SES may be an unrecognized determinant of vaccine responses. PPSV23 vaccination may reduce health disparities by SES in risk of pneumococcal pneumonia in asthmatics. While the mechanisms underlying this observation are studied, whether this observation is true for other vaccine titers need to be elucidated. RATIONALE: Yellow fever is a serious infectious disease caused by an arbov ırus. Caution is recommended in its indication and is contraindicated in the vast majority of primary immunodeficiencies. The objective of the present study was to evaluate the presence of adverse events and serious side effects after vaccination against yellow fever in individuals with a history of IgA deficiency. METHODS: Retrospective and descriptive study carried out with a review of records of patients diagnosed with IgA deficiency and who received the vaccine against yellow fever in the last eleven years, being followed up at a tertiary hospital in São Paulo, Brazil. RESULTS: Twenty-five patients with IgA deficiency were included in the study. They all received the vaccine against yellow fever. No patient had severe adverse events. Seventeen patients (68%) did not have any type of reaction, one (4%) presented local reaction (hyperemia and pruritus at the vaccine site) and three (12%) systemic events such as coryza, headache, fever, nausea and asthenia. The mean of CD4 + T lymphocytes was 915 mm 3 and total lymphocytes 2,000 mm 3 . CONCLUSIONS: In Brazil, most of the territory is considered an endemic area or a risk zone for yellow fever. We have to be cautious to contraindicate vaccination because the disease has high lethality and for which there is no specific treatment. We note from this study that vaccination in patients with IgA deficiency is possibly safe, contradicting current studies. Vaccination remains the most effective form of protection against disease.
